HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and raised the price target from $25 to $30.
August 16, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on ArriVent BioPharma and raised the price target from $25 to $30.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for ArriVent BioPharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100